Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.05 0.93% 5.45 218,047 11:50:51
Bid Price Offer Price High Price Low Price Open Price
5.20 5.70 5.45 5.40 5.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.80 -0.13 5
Last Trade Time Trade Type Trade Size Trade Price Currency
15:37:39 O 16,813 5.39 GBX

Physiomics (PYC) Latest News

More Physiomics News
Physiomics Investors    Physiomics Takeover Rumours

Physiomics (PYC) Discussions and Chat

Physiomics Forums and Chat

Date Time Title Posts
03/12/202015:38Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni8,968
30/11/202014:293 Years ago today1
29/11/202014:533 Years ago today-
15/10/202007:29PHYSIOMICS plc Virtual Tumor platform4,956
30/9/201907:08PYC - Podcast-

Add a New Thread

Physiomics (PYC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:37:405.3916,813906.22O
15:19:305.3913,074704.03O
12:40:305.6830,0001,702.50O
12:27:215.687,454423.01O
12:22:245.682,836160.94O
View all Physiomics trades in real-time

Physiomics (PYC) Top Chat Posts

DateSubject
04/12/2020
08:20
Physiomics Daily Update: Physiomics Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 5.40p.
Physiomics Plc has a 4 week average price of 5.25p and a 12 week average price of 5.25p.
The 1 year high share price is 17.10p while the 1 year low share price is currently 1.35p.
There are currently 97,334,778 shares in issue and the average daily traded volume is 641,222 shares. The market capitalisation of Physiomics Plc is £5,304,745.40.
16/10/2020
09:08
davevt: And yet another free of charge contract for pyc. Well probably not Free, but 35k, but they don't like to mention it anymore as every time they did the share price went down. Bless the fools on the Muppet board..'some of these contracts can be worth millions'. No, not ever. Learn what the company does, what pyc charge, then you'll know why.
16/10/2020
08:54
the stigologist: One does sometimes despair at the feeble intellect of your typical AIM investor. Over on Twitter we've had self proclaimed 'encyclopedic knowledge of 100s of AIM Companies' Riddler claim PYC are '£200k off profitability' At last weeks Presentation the Company had a big slide showing they made a 'Loss After Tax' of £64k. (So saying they are £200k off profitability is a 200% over-estimation) Today's RNS is a 'RNS-NON' this means the NOMAD do not deem it 'significant' under AIM rules which stipulate any contract has to be 5% of Revenue to qualify. I doubt both Bicycle and Merck got up Friday morning and signed off on 'sub 5% of PYC revenue' contracts. For Investors the significance is as follows :- These Modelling and Simulation contracts are 'bread and butter' stuff for PYC Bicycle (founded by Nobel Prize winning scientist) and with a $1.7bn licensing deal with Roche Genentech is a very very exciting Company. Simply growing alongside them is going to be a great marketing thing for PYC. Why shouldn't PYC shout it from the rooftops. We've now won 8! contracts on 4 of BCYC's assets !! Bicycle clearly like what Physiomics provide to them. There is a glowing customer testimonial they have supplied which is on PYC website. Merck (The German Merck. Merck KGaA) just happens to be one of the most innovative of the Big Pharma companies worldwide. In Immuno-oncology they are so hot they partner with GSK and Pfizer. Again to have a huge Company like Merck constantly coming back to use the services of a small consultancy like Physiomics is a huge indicator of the excellence of PYC tech and expertise. BUT... Once again for the slow students at the back these are just 'bread and butter' contracts for PYC now In the recent Investor Presentation Dr Jim Millen told us that side of the business should take care of itself... (having grown it from £0.2m in sales to £0.8m in sales in just 3 years) he is now looking to ACCELERATE Physiomics growth via (AND THIS IS THE BIG NEWS TO LOOK FORWARD TO) - Collaboration with a larger CRO (in discussions with several) - Seeking partnership with Established Players in the Personalised Medicine field to get regulatory approval and commercial traction for their Blue Sky exciting growth venture in Precision Dosing for Cancer (already funded to tune of £200k by Govt's Innovate UK, with additional £150k grant Clinical Trial to start soon at NHS Portsmouth Technology Trial Unit) - Potential upside from clients drugs being licensed (We know PYC get a share of ANY licensing income on Valirx's VAL201 and Sareum's SRA737. They may also have a share on CYCC Cyclacel's Seliciclib currently in various trials around the World including for Rheumatoid Arthritis and possibly soon Covid at University of Edinburgh).
05/10/2020
23:08
davevt: Stig, those two companies already do what pyc do....and for ALL drugs, not just cancer ones. In fact all simulations companies do what pyc does. That's why those companies have all the customers, all the revenues, all the market caps...and pyc doesn't. Pyc do one little thing and one thing only. They work out optimum doses of cancer drugs...not for the general public....just for test subjects in clinical trials. That's it!
23/9/2020
10:28
the stigologist: Worth laying out why this could be huge for PYC and arguably maybe even bigger and better for PYC than for VAL! 1. PYC have a FREE carried interest. We won't have to meet future costs of VAL201 (or VAL overheads) i.e. Trials costs/share dilution of Phase II/Phase III 2. Any VAL success in demonstrating SRC Inhibition approach may mean PYC can sell their SRC Inhibition modelling and simulation skills to other Companies looking to follow similar approach (maybe outside of Prostate Cancer as contract with VAL may have included a non-compete clause) 3. I believe Physiomics deliberately mentioned VAL201 in their August tweet because VAL have already approached them with regards to potentially engaging PYC to do modelling and simulation work on any future Phase II/III trial either for optimal dosing or potential combinations with potential Partner drugs?
18/9/2020
07:06
albert3591: No rns today then girls,those straws you are clutching must be getting rather crushed,a bit like pyc share price lol
16/9/2020
16:07
albert3591: I love it when someone says have added,it would be rude not to.Should pyc share price get to 20p the dipsticks would still be saying topped up today bargain.well they have been doing so for quite a while now and they ain’t up a penny piece.
08/9/2020
09:18
davevt: Jung, why are you trying to convince people to buy shares? You're a share holder right? So surely you realise trying to more holders in before news is completely detrimental to the share price rising. Are you trying to keep the share price from going up on news? Why would you want to do that? Makes no sense whatsoever... Please explain..
07/9/2020
11:35
the stigologist: Why PYC Physiomics stock could EXPLODE higher in September 2020 Share Price : 8p Shares in issue : 97m Market Cap : £8m Cash : £1m Revenue : £0.8m p.a. This comment (see Fig.1) was shared on VAL Valirx BB's this weekend Clearly knowledgeable VAL investors are very bullish on the upcoming VAL201 Phase I/II Clinical Trial results in Prostate Cancer (due in next few days/weeks) IF (still a big IF) VAL201 results are good they look like they will be in prime position to licence their VAL201 drug to a Big Pharma THREE/FOUR MAJOR POTENTIAL POSITIVES FOR PHYSIOMICS from Valirx's VAL201 success 1. IF VAL licence VAL201 Physiomics are entitled to 'Share of ANY licensing income' (licensing income includes i) Upfront fees ii) Development Milestones iii) Royalties when drug goes on Commercial sale. This could be UTTERLY TRANSFORMATIONAL to Physiomics finances and business. See Fig.5 for examples of Pharma licensing deal values. Any FREE share of those sort of revenues in event of VAL201 showing good results in Phase I/II and then being licensed to a Mid/Big Cap Pharma will be HUGE news for £8m Market Cap ; £0.8m revenue / P&L breakeven Physiomics. 2. IF VAL201 is successful it will have proven that VAL's approach of SRC Inhibition is important and successful this is likely to lead to i) VAL using Physiomics modelling and simulation knowledge of SRC Inhibition pathways for further work on VAL201 or improved 2nd generation devleopments of VAL201, this may also mean more Modelling and Simulation work from whoever VAL partners VAL201 with 3. Physiomics success in Modelling and Simulation of the SRC Inhibition pathway may also mean other Cancer drug companies working on this pathway also come to Physiomics for help in developing their drugs. It is worth noting i) The biggest currently selling Prostate Cancer drug is Astellas's Xtandi (about $2bn+ p.a.) ii) Physiomics recently signed up Astellas (19th Largest Pharma in the World) as a client on a mystery cancer drug project 4. There are suggestions that SRC inhibition is important in other disease pathways. Maybe even Covid19. Could Physiomics knowledge of these pathways and work at the leading edge of Cancer modelling with likes of Merck and Astellas help Companies in their investigation of other SRC Inhibition drugs? Or Combining SRC Inhibition drugs with leading Immuno-Oncology drugs such as Keytruda/Opdivo ? Fig.1 Grace83 post on VAL LSE BB Fig.2 Valirx/University College London poster presentation on VAL201 Fig.3 Physiomics tweet in August mentioning VAL201 and their other work with Cancer drugs which are demonstrating potential COVID efficacy Fig.4 Valirx CEO Suzi Dilly confirming that the Valirx-Physiomics revenue share agreement dating from 2011 remains in place Fig.5 Potential Upfront Licence Fees Pharma Companies Pay in Phase I,II,III deals (2011-16)
06/9/2020
09:50
davevt: Hod, I agree, if you're an idiot and have no idea what pyc does, then you'd think it's 'rich content'. Here's the facts. Pyc only do dose estimation for known working cancer drugs, and charge 35k for each one. I mean, seriously, that's all they do, a trivial and minor service that drug companies already DO THEMSELVES. May it be quicker? Sure? More accurate more percent of the times? Maybe? Are they the only company that does it? NOPE. Is it a crucial service? NOPE.. They have been around 20 years and every pharma that exists will already know about them. The do less turnover than your local pub and have never made a profit, as that isn't their business model. All of the proper Biotech companies do what little pyc do and a hundred times more, hence why when Stig labels them as 'comparitors' he fails to grasp the fact they are doing hundreds of millions in revenues and have all the pharmas behind them, and pyc doesn't.. Oh by the way, just got back from the boot sale....Jim and his pyc crew were there...first time they've ever made a profit 😂
06/9/2020
08:51
the stigologist: Why PYC Physiomics stock could EXPLODE higher in September 2020 Share Price : 8p Shares in issue : 97m Market Cap : £8m Cash : £1m Revenue : £0.8m p.a. This comment (see Fig.1) was shared on VAL Valirx BB's this weekend Clearly knowledgeable VAL investors are very bullish on the upcoming VAL201 Phase I/II Clinical Trial results in Prostate Cancer (due in next few days/weeks) IF (still a big IF) VAL201 results are good they look like they will be in prime position to licence their VAL201 drug to a Big Pharma THREE/FOUR MAJOR POTENTIAL POSITIVES FOR PHYSIOMICS from Valirx's VAL201 success 1. IF VAL licence VAL201 Physiomics are entitled to 'Share of ANY licensing income' (licensing income includes i) Upfront fees ii) Development Milestones iii) Royalties when drug goes on Commercial sale. This could be UTTERLY TRANSFORMATIONAL to Physiomics finances and business. See Fig.5 for examples of Pharma licensing deal values. Any FREE share of those sort of revenues in event of VAL201 showing good results in Phase I/II and then being licensed to a Mid/Big Cap Pharma will be HUGE news for £8m Market Cap ; £0.8m revenue / P&L breakeven Physiomics. 2. IF VAL201 is successful it will have proven that VAL's approach of SRC Inhibition is important and successful this is likely to lead to i) VAL using Physiomics modelling and simulation knowledge of SRC Inhibition pathways for further work on VAL201 or ii) improved 2nd generation devleopments of VAL201, this may also mean iii) more Modelling and Simulation work from whoever VAL partners VAL201 with 3. Physiomics success in Modelling and Simulation of the SRC Inhibition pathway may also mean other Cancer drug companies working on this pathway also come to Physiomics for help in developing their drugs. It is worth noting i) The biggest currently selling Prostate Cancer drug is Astellas's Xtandi (about $2bn+ p.a.) ii) Physiomics recently signed up Astellas (19th Largest Pharma in the World) as a client on a mystery cancer drug project 4. There are suggestions that SRC inhibition is important in other disease pathways. Maybe even Covid19. Could Physiomics knowledge of these pathways and work at the leading edge of Cancer modelling with likes of Merck and Astellas help Companies in their investigation of other SRC Inhibition drugs? Or Combining SRC Inhibition drugs with leading Immuno-Oncology drugs such as Keytruda/Opdivo ? Fig.1 Grace83 post on VAL LSE BB Fig.2 Valirx/University College London poster presentation on VAL201 Fig.3 Physiomics tweet in August mentioning VAL201 and their other work with Cancer drugs which are demonstrating potential COVID efficacy Fig.4 Valirx CEO Suzi Dilly confirming that the Valirx-Physiomics revenue share agreement dating from 2011 remains in place Fig.5 Potential Upfront Licence Fees Pharma Companies Pay in Phase I,II,III deals (2011-16)
Physiomics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
PYC
Physiomics
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201204 18:24:55